There were 1,559 press releases posted in the last 24 hours and 457,120 in the last 365 days.

Chiasma to Report First Quarter Financial Results on May 9, 2019

Company to host conference call and webcast at 5:00pm ET

/EIN News/ -- WALTHAM, Mass., April 30, 2019 (GLOBE NEWSWIRE) -- Chiasma, Inc. (Nasdaq: CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious chronic diseases, today announced that it will host a conference call and live audio webcast on Thursday, May 9, 2019 at 5:00 p.m. Eastern Time to discuss financial results for the quarter ended March 31, 2019 and to provide a business update.

Conference Call Details
Thursday, May 9th @ 5pm Eastern Time
Domestic: 877-407-4018
International: 201-689-8471
Conference ID: 13690157

About Chiasma
Chiasma is focused on improving the lives of patients who face challenges associated with their existing treatments for rare and serious chronic diseases. Employing its Transient Permeability Enhancer (TPE®) technology platform, Chiasma seeks to develop oral medications that are currently available only as injections. In October 2018, the Company completed enrollment in CHIASMA OPTIMAL, its third Phase 3 clinical trial for its octreotide capsules product candidate, conditionally trade-named MYCAPSSA®, for the maintenance therapy of adult patients with acromegaly in whom prior treatment with somatostatin analogs has been shown to be effective and tolerated. Prior to trial initiation, the Company reached agreement with the FDA on the design of the trial through a special protocol assessment. Chiasma is headquartered in Waltham, MA with a wholly-owned subsidiary in Israel. MYCAPSSA, TPE and CHIASMA are registered trademarks of Chiasma. For more information, please visit the Company’s website at

Ashley R. Robinson
LifeSci Advisors, LLC

ChiasmaLogo (2).jpg